Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Kountourakis P, Missitzis I, Doufexis D, Zobolas V, Pissakas G, Arnogiannaki N, Maliou S, Sotiropoulou A, Ardavanis A. Kountourakis P, et al. Among authors: arnogiannaki n. J Cancer Res Clin Oncol. 2011 Feb;137(2):221-8. doi: 10.1007/s00432-010-0878-8. Epub 2010 Apr 13. J Cancer Res Clin Oncol. 2011. PMID: 20387073 Clinical Trial.
Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G. Ardavanis A, et al. Among authors: arnogiannaki n. Oncologist. 2006 Jun;11(6):563-73. doi: 10.1634/theoncologist.11-6-563. Oncologist. 2006. PMID: 16794236 Free article. Clinical Trial.
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN. Fortis SP, et al. Among authors: arnogiannaki n. J Immunother Cancer. 2017 Apr 18;5:39. doi: 10.1186/s40425-017-0240-7. eCollection 2017. J Immunother Cancer. 2017. PMID: 28428887 Free PMC article.
Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.
Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, Pawelec G, Perez SA, Baxevanis CN. Fortis SP, et al. Among authors: arnogiannaki n. J Immunother Cancer. 2017 May 30;5:48. doi: 10.1186/s40425-017-0248-z. eCollection 2017. J Immunother Cancer. 2017. PMID: 28572978 Free PMC article.
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
Sofopoulos M, Fortis SP, Vaxevanis CK, Sotiriadou NN, Arnogiannaki N, Ardavanis A, Vlachodimitropoulos D, Perez SA, Baxevanis CN. Sofopoulos M, et al. Among authors: arnogiannaki n. Cancer Immunol Immunother. 2019 Nov;68(11):1733-1745. doi: 10.1007/s00262-019-02407-8. Epub 2019 Oct 9. Cancer Immunol Immunother. 2019. PMID: 31598757 Free PMC article.
48 results